BRCCH Seminar 20 Oct - Malaria Prevention: Progress and Prospects


Visual: Swiss TPH, fairpicture


Description:  The BRCCH cordially invites you to join our seminar addressing the progress and prospects of malaria prevention. Prof Simon Draper (University of Oxford, UK) will highlight the challenges, successes and future developments of vaccine-based solutions. Then, Prof Melissa Penny (Swiss TPH) will share her work on data analytics and modelling as product development support. Finally, Prof Evelyn Korkor Ansah (University of Health and Allied Sciences, Ghana) will provide insights into vaccine implementation and equitable distribution.

When: Thursday, October 20th, 2022 from 15:00-16:30 CET

Where: Hybrid Zoom / Kollengienhaus, Hörsaal 116, Petersgraben 50, 4051 Basel

Zoom Registration: HERE

In-person Registration (encouraged but not mandatory): HERE


      • Welcome by Prof Marcel Tanner (Swiss Academy of Arts and Sciences and Swiss TPH)
      • Prof Simon Draper (University of Oxford, UK): Malaria Vaccines – Recent Advances and Future Challenges (20 min)
      • Prof Melissa Penny (Swiss TPH): Data Analytics and Modelling Supporting Novel Malaria Prevention (20 min)
      • Prof Evelyn Korkor Ansah (University of Health and Allied Sciences, Ghana): Lessons from Malaria Vaccine Implementation in Ghana (20 min)
      • Q&A and Closing
      • Networking Apéro

Keynote speakers:

Prof Simon Draper

University of Oxford, UK

Simon Draper is a Professor of Vaccinology and Translational Medicine. The research undertaken in the Draper group focuses on the development of novel and improved approaches to blood-stage malaria vaccine design, as well as aiming to better understand molecular mechanisms of vaccine-induced immunity to blood-stage malaria infection. In particular, the group’s research interests span: strategies for improved vaccine antigen identification; development of improved vaccine delivery strategies; assessment of quantitative antibody correlates of protective immunity, and assessment of human vaccine-induced antibody responses to guide structure-based immunogen design and to better understand protective mechanisms of immunity.

A critical strength of the group is a strong dual focus on preclinical vaccine development in parallel with early-phase clinical vaccine testing and experimental medicine studies. There is a strong translational emphasis, with the most promising new approaches and/or candidate vaccines feeding into the Blood-Stage Malaria Clinical Trials Programme.

Prof Melissa Penny

Swiss Tropical and Public Health Institute & University of Basel, Switzerland

Melissa Penny is a professor and Head of the Disease Modelling research unit at Swiss TPH. She has more than 16 years of experience developing mathematical and computational models to provide quantitative evidence to support infectious disease control and elimination decisions, particularly for product development and policy decisions on new interventions.

She leads and has led international multi-institute consortia to provide evidence to WHO and other stakeholders for decision-making on new malaria interventions. This evidence includes the likely public health impact and cost-effectiveness of new interventions, such as the world’s first malaria vaccine RTS,S/AS01 (2015 and 2021), and, more recently, novel immune therapies. Her recent research focuses on developing data- and epidemiology-informed mathematical models and associated algorithms to understand pathogen, host, and intervention dynamics and to inform decisions during product development through implementation and policy recommendations. This work includes new approaches using mechanistic models to inform quantitative target product profiles for novel malaria tools. Her group has also developed new models of SARS-CoV-2 dynamics and applied them to inform decisions on novel interventions against COVID-19. She is also a member of several WHO scientific or technical working groups and WHO Guideline Development Groups.

She also leading a BRCCH-funded project to inform novel medical interventions against SARS-Cov-2 (find out more here).


Prof Evelyn Korkor Ansah

University of Health and Allied Sciences, Ghana

Evelyn Korkor Ansah is the Director of the Centre for Malaria Research. She is a Public Health Physician, an Epidemiologist, a fellow of the Ghana College of Physicians and Surgeons and a Rockefeller Foundation Bellagio Fellow. Prof Ansah was the Vice Chair of the Global Fund’s Technical Review Panel (TRP) to combat HIV/AIDS, Tuberculosis and Malaria until 2019. She currently serves on the WHO’s Malaria Policy Advisory Committee (MPAC) and Malaria Elimination Oversight Committee (MEOC). In addition to this, she serves on the Independent Evaluation Panel (IEP) of the Global Fund to fight HIV/AIDS and Malaria. Prior to this, she served on the Technical Evaluation Reference Group (TERG) of the Global Fund, the Bellagio Academic Selection Panel of the Rockefeller Foundation, and the Steering Committee of the ACT Consortium (involving over 15 institutions in several countries).

Her key research interests are malaria case management, diagnostics, health systems, maternal health and capacity building for health research. To this end, she has conducted a number of multi-country and local studies including clinical trials and health systems research.